Annual Report

Overview

The report presents 2022 as a breakthrough year, led by positive Phase 2 data for videncel in acute myeloid leukemia and first positive clinical data in ovarian cancer. It describes preparation for an ilixadencel trial in gastrointestinal stromal tumors and the development of a memory NK-cell research program. The group reported no revenue for the year and remained focused on advancing its clinical and preclinical pipeline.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services